ID: ALA1950797

Max Phase: Preclinical

Molecular Formula: C19H20N2O5

Molecular Weight: 356.38

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(O)[C@H]1NCCN(C(=O)CCc2ccc3ccccc3c2)[C@H]1C(=O)O

Standard InChI:  InChI=1S/C19H20N2O5/c22-15(21-10-9-20-16(18(23)24)17(21)19(25)26)8-6-12-5-7-13-3-1-2-4-14(13)11-12/h1-5,7,11,16-17,20H,6,8-10H2,(H,23,24)(H,25,26)/t16-,17+/m0/s1

Standard InChI Key:  NBUCTWIXCOYPEG-DLBZAZTESA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 356.38

Molecular Weight (Monoisotopic): 356.1372

AlogP: 1.11

#Rotatable Bonds: 5

Polar Surface Area: 106.94

Molecular Species: ACID

HBA: 4

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 2.75

CX Basic pKa: 7.81

CX LogP: -0.64

CX LogD: -3.92

Aromatic Rings: 2

Heavy Atoms: 26

QED Weighted: 0.74

Np Likeness Score: -0.09

References

1. Irvine MW, Costa BM, Dlaboga D, Culley GR, Hulse R, Scholefield CL, Atlason P, Fang G, Eaves R, Morley R, Mayo-Martin MB, Amici M, Bortolotto ZA, Donaldson L, Collingridge GL, Molnár E, Monaghan DT, Jane DE..  (2012)  Piperazine-2,3-dicarboxylic acid derivatives as dual antagonists of NMDA and GluK1-containing kainate receptors.,  55  (1): [PMID:22111545] [10.1021/jm201230z]

Source

Source(1):

• Scientific Literature